Toronto Dominion Bank
RVNC

Toronto Dominion Bank’s Revance Therapeutics, Inc. RVNC Stock Holding History

Toronto Dominion Bank’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5
Closed -$13 – 1479
2024
Q2 		$13 Hold
5
– – ﹤0.01% 1425
2024
Q1 		$25 Hold
5
– – ﹤0.01% 1385
2023
Q4 		$44 Hold
5
– – ﹤0.01% 1520
2023
Q3 		$57 Hold
5
– – ﹤0.01% 1732
2023
Q2 		$0 Hold
5
– – ﹤0.01% 1857
2023
Q1 		$0 Buy
+5
New +$156 ﹤0.01% 1760
2022
Q3 		– Sell
-65
Closed -$1K – 1750
2022
Q2 		$1K Buy
+65
New +$1K ﹤0.01% 1266

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Toronto Dominion Bank's RVNC Position: Q3 2024 in Review

Toronto Dominion Bank sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 5 shares — an estimated $13 sold.

Toronto Dominion Bank first reported a position in RVNC in Q2 2022 and held it in 7 quarters. The position peaked at $1K in Q2 2022. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • Toronto Dominion Bank reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • Toronto Dominion Bank sold 5 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $13.
  • Toronto Dominion Bank first reported a position in Revance Therapeutics, Inc. in Q2 2022 and held it in 7 quarters.
  • Toronto Dominion Bank's Revance Therapeutics, Inc. position peaked at $1K in Q2 2022.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Toronto Dominion Bank's 13F filing for Q3 2024, filed 14 Nov 2024.